05:30 AM EDT, 06/24/2025 (MT Newswires) -- Amgen ( AMGN ) said late Monday its phase 2 trial of MariTide showed up to 20% average weight loss at 52 weeks in obese people without any evidence of a plateau.

Gastrointestinal side effects were mostly mild to moderate and occurred early, with fewer issues in dose escalation arms and no new safety signals identified, the company said.

The treatment also led to robust reductions in HbA1c and improvements in cardiometabolic markets, including waist circumference and blood pressure, Amgen ( AMGN ) said.

The company also said participants with obesity and type 2 diabetes lost up to 17% of their weight, compared with 1.4% in the placebo group.

Amgen ( AMGN ) added that phase 3 MariTime weight management studies are underway, with trials for heart failure, sleep apnea, and cardiovascular disease planned for this year.